These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9525650)

  • 1. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.
    Li A; Katinger H; Posner MR; Cavacini L; Zolla-Pazner S; Gorny MK; Sodroski J; Chou TC; Baba TW; Ruprecht RM
    J Virol; 1998 Apr; 72(4):3235-40. PubMed ID: 9525650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins.
    Li A; Baba TW; Sodroski J; Zolla-Pazner S; Gorny MK; Robinson J; Posner MR; Katinger H; Barbas CF; Burton DR; Chou TC; Ruprecht RM
    AIDS Res Hum Retroviruses; 1997 May; 13(8):647-56. PubMed ID: 9168233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
    Mascola JR; Louder MK; VanCott TC; Sapan CV; Lambert JS; Muenz LR; Bunow B; Birx DL; Robb ML
    J Virol; 1997 Oct; 71(10):7198-206. PubMed ID: 9311792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
    J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    Mascola JR; Lewis MG; Stiegler G; Harris D; VanCott TC; Hayes D; Louder MK; Brown CR; Sapan CV; Frankel SS; Lu Y; Robb ML; Katinger H; Birx DL
    J Virol; 1999 May; 73(5):4009-18. PubMed ID: 10196297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Baba TW; Liska V; Hofmann-Lehmann R; Vlasak J; Xu W; Ayehunie S; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Lu Y; Wright JE; Chou TC; Ruprecht RM
    Nat Med; 2000 Feb; 6(2):200-6. PubMed ID: 10655110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
    Ruprecht RM; Hofmann-Lehmann R; Smith-Franklin BA; Rasmussen RA; Liska V; Vlasak J; Xu W; Baba TW; Chenine AL; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Montefiori DC; McClure HM
    Transfus Clin Biol; 2001 Aug; 8(4):350-8. PubMed ID: 11642027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.
    Hofmann-Lehmann R; Vlasak J; Rasmussen RA; Smith BA; Baba TW; Liska V; Ferrantelli F; Montefiori DC; McClure HM; Anderson DC; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Katinger H; Stiegler G; Cavacini LA; Posner MR; Chou TC; Andersen J; Ruprecht RM
    J Virol; 2001 Aug; 75(16):7470-80. PubMed ID: 11462019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.
    Song B; Cayabyab M; Phan N; Wang L; Axthelm MK; Letvin NL; Sodroski JG
    Virology; 2004 Apr; 322(1):168-81. PubMed ID: 15063126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.
    Xu W; Smith-Franklin BA; Li PL; Wood C; He J; Du Q; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
    J Hum Virol; 2001; 4(2):55-61. PubMed ID: 11437315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
    Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
    J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.
    Si Z; Cayabyab M; Sodroski J
    J Virol; 2001 May; 75(9):4208-18. PubMed ID: 11287570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
    J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.
    Laal S; Burda S; Gorny MK; Karwowska S; Buchbinder A; Zolla-Pazner S
    J Virol; 1994 Jun; 68(6):4001-8. PubMed ID: 7514683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
    Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
    J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
    Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
    Cheng-Mayer C; Brown A; Harouse J; Luciw PA; Mayer AJ
    J Virol; 1999 Jul; 73(7):5294-300. PubMed ID: 10364275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
    Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
    J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.